Symbols

HBIO

Harvard Bioscience·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Price Hits 52-week Low

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HBIO

Harvard Bioscience, Inc.

A developer of life sciences equipment to support research and drug discovery

Industry

Life Science Tools and Services

Established Date

Listing Date

12/07/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

316

Fiscal Year Ends

12-31

Website

www.harvardbioscience.com

Security Type

Common stock

Office address

84 October Hill Road, Holliston, Massachusetts 01746

Business

Introduction

Harvard Bioscience, Inc., was incorporated in Delaware in September 2000. The company is a leading developer, manufacturer and marketer of technologies, products and services required for life science applications, including research, drug discovery and preclinical testing. With operations in the United States, Europe and China, it serves customers worldwide through direct sales and distribution channels.

Company Financials

EPS

HBIO has released its 2025 Q4 earnings. EPS was reported at -0.06, versus the expected 0.04, missing expectations. The chart below visualizes how HBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HBIO has released its 2025 Q4 earnings report, with revenue of 23.73M, reflecting a YoY change of -3.34%, and net profit of -2.85M, showing a YoY change of -15916.67%. The Sankey diagram below clearly presents HBIO's revenue sources and cost distribution.